Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Apollomics received a notification from Nasdaq that it is not in compliance with the minimum market value of listed securities requirement of $35 million after falling below that threshold for 30 consecutive business days. The company has 180 calendar days, until December 15, 2026, to regain compliance by maintaining a market value of at least $35 million for ten consecutive business days or face potential delisting. Separately, the company terminated its collaboration with Launxp International due to a material breach regarding a $3.8 million payment, resulting in Apollomics regaining rights to vebreltinib (APL-101) in Asia.
Key figures
- Mvls threshold
- 35000000
- Unpaid payment
- 3800000
- Cure period days
- 180
- Compliance deadline
- 2026-12-15
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.